Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-KDM5B is a synthetic small interfering RNA (siRNA) molecule designed to specifically target and suppress expression of the lysine-specific demethylase 5B gene (KDM5B) via RNA interference. KDM5B is a histone demethylase that regulates chromatin structure and gene expression by removing methyl groups from H3K4me2/3 residues, thereby leading to transcriptional repression. si-KDM5B acts by binding to KDM5B mRNA, resulting in its degradation and decreased translation of the KDM5B protein. Knockdown of KDM5B using si-KDM5B increases H3K4 trimethylation, alters cell cycle dynamics, and has variable effects on cell proliferation and viability depending on cancer cell type and chemoresistance status. In sensitive neuroblastoma and hepatocellular carcinoma cell lines, si-KDM5B inhibits proliferation and tumorigenicity, arrests the cell cycle at the G1/S phase, and can increase sensitivity to chemotherapy. The molecule is primarily utilized as a research tool in functional genomics studies, often for mechanistic investigation and target validation rather than as an approved therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on si-KDM5B.